At the molecular level, we observed a reduced frequency of MAP3K1 mutations in kinase fusion-positive cases compared with that in fusion-negative cases, both in the overall cohort and in HR+/HER2‒ breast cancer (Supplementary Figs. S3d, S4). This evidence concerns the gene ERBB2 and breast carcinoma.